Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-83

In regards to Servier deal with Precision Bio an article here from 6/05/2021 link below Originally they paid $1.6 billion, how did we get it so cheap or are the milestone payments expected to be much higher than we think?

PPF Group | Precision Bio reacquires global rights to its allogenic CAR-T programs

Precision Bio reacquired rights to set of its CAR-T programs from Servier
A collection of CAR T-cell programs originally licensed by Precision Biosciences to Baxalta in a $1.6 billion deal are, after handoffs to Shire and Servier, back where they began. Precision will reacquire all development and commercial rights to the programs, including two clinical-stage CD19-targeting allogeneic CAR T candidates, from Servier for $1.25 million in cash, plus the waiver of earned but as-yet unpaid milestones totaling $18.75 million. The clinical programs included in the deal are Precision's lead candidate, PBCAR-0191 (azercabtagenezapreleucel), an allogeneic CAR T-cell candidate for the potential treatment of NHL, B-cell ALL and other cancers, and PBCAR-19B, another allogeneic T-cell candidate for the potential treatment of CD19-expressing hematologic malignancies. It is slated to enter the clinic for NHL in May. Programs for four additional product targets are also returning to Precision. Preclinical data on PBCAR-19B looks like the most innovative and compelling strategy in the allo CAR T field. Servier has certain rights of negotiation if Precision elects to repartner the programs. Servier also remains eligible to receive milestones and low-to mid-single-digit royalties on the programs, subject to product development milestones. In addition to PBCAR-0191 and PBCAR-19B, Precision's wholly owned pipeline now includes PBCAR-20A, an allogeneic CAR T-cell candidate targeting CD20; PBCAR-269A, an allogeneic CAR T-cell therapy targeting BCMA; and the four hematologic and solid tumor programs just repurchased from Servier